On March 29, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner continues our miniseries to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.
To learn more about the topics in this episode:
- Emergent makes history with first FDA nod for over-the-counter naloxone
- Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts
- Adapt tests ads urging opioid users' loved ones to stock Narcan at home
- Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M
- Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod
- Virtual Roundtable: Remote Therapeutic Monitoring, The Future of Virtual Care Management
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.